Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – March 17, 2023) – Innocan Pharma Corporation INNO IP INNPF (the “Company” or “Innocan”), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.
Innocan CEO, Iris Bincovich, stated, “We are excited to announce the appointment of a dedicated internal team covering the financial, scientific, and legal aspects required to engage with prospective clients in the veterinary field. Our goal is to commercialize, partner, and/or sell Innocan’s intellectual property portfolio to veterinary indications. We believe there is significant potential in the veterinary market for our CBD-based products.”
CBD has been shown to have a wide range of therapeutic properties, including anti-inflammatory, analgesic, and anti-anxiety effects. The veterinary market is an important sector that can benefit from the potential therapeutic effects of CBD. The appointment of a dedicated internal team will foster engagement between Innocan and prospective clients in the veterinary field in order to explore potential collaborations and commercialization opportunities.
Innocan’s…
Original Author Link click here to read complete story..
